Drugs / CSL730
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04446000 | Sep 2020 → Mar 2023 | type III hypersensitivity disease | CSL Behring | Terminated | No outcome recorded |
| Phase 1 | NCT03375606 | Jan 2018 → Jun 2020 | — | CSL Behring | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSL730 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03375606 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant trivalent human IgG1 Fc multimer” NCT03375606 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT03375606 ↗ |